Christopher Anzalone, Ph.D.
Dr. Anzalone is the President and Chief Executive Officer of Arrowhead Research. He has a wealth of experience in nanotechnology, biotechnology, company-building, and venture capital. Prior to joining Arrowhead, Dr. Anzalone founded and built The Benet Group, a private equity firm focused on creating and building new nanobiotechnology companies from university-generated science. Included in The Benet Group's portfolio are investments in two nanotechnology companies: Nanotope Inc., a tissue regeneration company, and Leonardo Biosystems Inc., a cancer drug delivery company. Prior to Benet, Dr. Anzalone was a partner at the Washington DC-based private equity firm Galway Partners, LLC where he was in charge of sourcing, structuring, and building new business ventures. He was also the founding CEO of NanoInk, Inc., a leading nanolithography company.
Ken Myszkowski, MBA, CPA
Ken Myszkowski is Arrowhead's Chief Financial Officer. Mr. Myszkowski brings to Arrowhead a broad range of finance and accounting experience spanning two decades in both the public and private sectors, including senior level positions at two publicly traded energy companies and, earlier in his career, in two early stage technology companies.
Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a $200 million public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a $4 billion public energy company. Prior to Epcor, Mr. Myszkowski was controller for two start-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided on-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation, and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen & Co. in Chicago, Illinois.
Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant.
Bruce Given, M.D.
Dr. Given served as President, Chief Executive Officer and member of the Board of Directors of Encysive Pharmaceuticals. In addition, he has held senior operational roles with Johnson & Johnson as President, International for Ortho Clinical Diagnostics and Group Vice President and Head, Research and Development, Sales and Marketing for Janssen Pharmaceutica(US), as well as various executive and senior management positions at Sandoz Pharma Ltd., Sandoz Research Institute and Schering-Plough Corporation. Before entering the pharmaceutical industry, Dr. Given was on the medical faculty at the University of Chicago.
Since February 1, 2010, Dr. Given has served as Chief Executive Officer of Leonardo Biosystems, Inc., a company in which Arrowhead maintains a minority equity interest, and he also has served as a director of Calando Pharmaceuticals, Inc., a subsidiary of Arrowhead, since October 1, 2009. Additionally, Dr. Given has served on the Board of Directors of ICON, plc since 2004 and was elected Chairman in 2010. Dr. Given also serves on the Boards of Directors of Sembiosys Genetics Inc. and BioHouston, and is a member of the inCube Scientific Advisory Board. He previously served as a member of the CPRIT Commercialization Committee, the Texas Life Sciences Committee, the Technology Review Committee of MD Anderson Medical Center, and is past Chairman of the Rider University Scientific Advisory Board.
Thomas Schluep, Sc.D.
Dr. Schluep is an expert in translating delivery system and therapy innovations into pharmaceutical and biotechnology product candidates. Dr. Schluep was the Chief Scientific Officer of Insert Therapeutics, prior to its merger with Calando, where he headed drug discovery and development programs for the polymeric delivery system Cyclosert and the IT-101 candidate. While at Insert, he drove IT-101 from the laboratory to Phase I clinical trial in less than two years. Prior to joining Insert, Dr. Schluep was responsible for the non-viral gene therapy program at Canji, Inc., a wholly-owned subsidiary of Schering-Plough. At Canji, he successfully led an interdisciplinary team of scientists in their efforts to develop synthetic gene delivery vehicles for the systemic treatment of cancer with the p53 tumor suppressor gene. Prior to Canji, Dr. Schluep was a post-doctoral associate at the department of Chemical Engineering at the Massachusetts Institute of Technology. He received his Sc.D. in Process Engineering in 1995 and an MS in Biotechnology in 1989, both from the Swiss Federal Institute of Technology in Zurich, Switzerland.
David Lewis, Ph.D.
Dr. Lewis is a pioneer in the use of RNAi and was the first to show that siRNAs could be used to inhibit gene expression in multiple tissues of adult mammals. He is a co-inventor of DPC technology for targeted delivery of siRNA. Prior to his role as Site Head at the Madison facility, Dr. Lewis was the Program Director for RNAi at Mirus Bio Corporation, prior to its acquisition by Roche in October 2008.
Dr. Lewis received his B.S. degree in Biochemistry and Molecular Biology from the University of Wisconsin-Madison, and his Ph.D. degree in Biochemistry from Michigan State University. He went on to the Howard Hughes Medical Institute at the University of Wisconsin-Madison to perform post-doctoral studies where he developed viral and non-viral methods to modulate gene expression in animals, and discovered novel gene regulatory mechanisms involved in body patterning.
Dr. Lewis has authored 25 scientific papers and book chapters, has 19 patents, and has been awarded government-sponsored research grants totaling more than $5 million. He has given numerous invited speaking presentations at both scientific conferences and research institutions. He has served on several NIH review panels and is a lecturer in the Masters in Biotechnology Program at the University of Wisconsin-Madison.
David Rozema, Ph.D.
Dr. Rozema has served as the Program Director, Delivery Chemistry at the Roche-Madison facility since 2008 where he played a lead role in the development and synthesis of siRNA delivery vehicles. Prior to that he was a Senior Scientist at Mirus Bio where he oversaw the development of nucleic acid delivery chemistries including siRNA-polymer conjugates for in vivo delivery, and the design and synthesis of plasmid delivery vehicles with emphasis on the development of new endosomolytic strategies.
Dr. Rozema received his B.A. degree in Chemistry and Math from Calvin College, Grand Rapids, Michigan, and his Ph.D. in Chemistry from the University of Wisconsin-Madison. He performed his post-doctoral studies at the University of Utah where he focused on mechanistic studies of protein farnesyltransferase. Dr. Rozema has authored more than 14 papers and has been granted 25 patents.
As of May 7, 2013
outstanding = 31,305,317
authorized = 145,000,000
outstanding = 9,900 shares issued @ $1000 per share each shares convertible into 546 shares of common stock ( 5,409,836 shares of common stock)
authorized = 5,000,000